INmune Bio's Alzheimer's Drug XPro1595 Shows Statistically Significant Phase 2 Efficacy
INMB sits 33% above its 52-week low of $1.09.
Summary
INmune Bio announced statistically significant positive results from its Phase 2 MINDFuL Alzheimer's trial for XPro1595, demonstrating a treatment effect on an advanced white matter MRI biomarker. This is a major clinical validation for the drug, following its FDA Fast Track designation last month. The positive data is critical for the company, which has recently faced going concern warnings due to liquidity issues, and could significantly improve its prospects for future development and financing.
At the time of this announcement, INMB was trading at $1.45 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $37M. The 52-week trading range was $1.09 to $11.64. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: Reuters.